The widespread adoption of electronic health records (EHR) provides a unique and novel opportunity to improve the efficiency of clinical research processes. The European EHR4CR (Electronic Health Records for Clinical Research) 4-year project has developed a technological platform to enable the reuse of EHR data for clinical research. The objective of this cost-benefit assessment (CBA) is to assess the value of EHR4CR solutions compared to current practices. Methods Three clinical research scenarios were selected: Protocol feasibility assessment (S1), patient identification for recruitment (S2), and clinical study conduct (S3). The approach considered that the estimated reduction in actual person-time and costs of performing EHR4CR S1, S2, S3 applied to a Phase II or Phase III oncology clinical trial as a reference case would accelerate time to market (TTM). Probabilistic sensitivity analyses were conducted. Results When converting the efficiency gains realized with the EHR4CR platform into potential financial value for achieving faster TTM, the absolute mean cost-benefit for the global pharmaceutical oncology sector was estimated at €161m (S1), €46m (S2), €1'904m (S3), €204m (S1+S2), and up to €2'119m (S1+S2+S3) when the three scenarios were used sequentially.
. CBA Assumptions  Global multicenter Phase II or Phase III oncology study  Study conducted in 10-15 countries  Involving 100-150 clinical centres  Clinical study size: 450-1500 patients  Full time equivalent (FTE) = €687/day (estimated weighted average daily wage)  1 FTE = 220 days  50% reduction in actual person-time and costs for S1,S2,S3 tasks impacted by the EHR4CR platform  S1 assumes a reduction of 50% in the number of protocol amendments under EHR4CR conditions The EHR4CR European project, one of the largest public-private research partnership between the European Union and the EFPIA, has developed an advanced technological platform to enable the trustworthy reuse of hospital EHRs data for clinical research in Europe, and beyond. The objective of this CBA is to assess the potential value for pharmaceutical industry of adopting EHR4CR clinical research solutions versus current practices, as applied to oncology trials as a reference case.
By enabling the trustworthy reuse of hospital-based EHR patient-level data for clinical research, the EHR4CR breakthrough platform promises to transform clinical research environments, to enhance current practices, and to improve the overall efficiency of clinical research current frameworks. This CBA is the first study to assess the value of the EHR4CR platform compared to current practices. The results confirm that the EHR4CR-enabled clinical research scenarios, whether used individually, in combination, or in sequence within a clinical trial workflow, appear highly efficient, reducing the actual person-time and operational costs for conducting Phase II-III clinical trials in oncology as the reference case. Should the efficiency gains realized with the EHR4CR platform translate into achieving marketing authorization faster, and delivering innovative medicines to healthcare sooner, this economic evaluation establishes that the overall benefits and added value to global pharmaceutical industry would be substantial. While these results suggest an early adoption of EHR4CR solutions, further research is warranted to assess the EHR4CR value in real life context, once the platform has been fully deployed for enhancing clinical research, across clinical trial phases and therapeutic areas, in Europe, and beyond.
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